Table 1.
Patient, tumor, and treatment characteristics for entire patient population and for subgroup of patients who completed the planned course of treatment*
| Characteristic | All patients (n = 256) | Patients completing planned treatment (n = 192) |
|---|---|---|
| Patient | ||
| Follow-up of patients alive | ||
| Median (mo) | 64 | 78 |
| Range (mo) | 7–240 | 7–232 |
| Age (y) | ||
| Median | 49 | 49 |
| Range | 24–76 | 24–76 |
| Race/ethnicity | ||
| White | 184 (72%) | 141 (73%) |
| African American | 30 (12%) | 21 (11%) |
| Hispanic | 34 (13%) | 23 (12%) |
| Asian | 4 (2%) | 3 (2%) |
| Other | 4 (2%) | 4 (2%) |
| Menopausal status | ||
| Pre/peri | 97 (38%) | 77 (56%) |
| Post | 124 (48%) | 108 (40%) |
| Unknown | 35 (14%) | 7 (4%) |
| Tumor | ||
| N stage | ||
| N0 | 36 (14%) | 26 (14%) |
| N1 | 102 (40%) | 81 (42%) |
| N2 | 84 (33%) | 62 (32%) |
| N3 | 22 (9%) | 17 (9%) |
| Nx | 12 (5%) | 6 (3%) |
| Supraclavicular nodes | ||
| Positive | 35 (14%) | 17 (9%) |
| Negative | 187 (73%) | 144 (75%) |
| Unknown | 34 (13%) | 31 (16%) |
| ER status | ||
| Negative | 119 (46%) | 93 (48%) |
| Positive | 66 (26%) | 50 (26%) |
| Unknown | 77 (30%) | 49 (26%) |
| Her2neu status | ||
| Negative | 37 (14%) | 24 (13%) |
| Positive | 21 (8%) | 20 (10%) |
| Unknown | 198 (77%) | 148 (77%) |
| Treatment | ||
| Neoadjuvant | 244 (95%) | 183 (95%) |
| chemotherapy | ||
| Taxane used | 80 (31%) | 77 (40%) |
| Response to chemotherapy† | ||
| CR | 43 (21%) | 42 (23%) |
| PR | 118 (59%) | 111 (61%) |
| NR | 40 (20%) | 30 (16%) |
| Surgical margin status | ||
| Negative | 133 (52%) | 133 (70%) |
| Close/positive | 26 (10%) | 16 (8%) |
| Unknown | 97 (38%) | 43 (22%) |
| No. of nodes removed | ||
| Median | 13 | 13 |
| Range | 0–43 | 0–43 |
| No. of nodes pathologically positive | ||
| 0–3 | 90 (47%) | 90 (47%) |
| ≥4 | 102 (53%) | 102 (53%) |
| XRT fractionation | ||
| Once daily | 47 (20%) | 38 (20%) |
| Twice daily | 204 (80%) | 154 (80%) |
| XRT dose | ||
| Median 60 Gy | NA | 79 (41%) |
| Range (Gy) | NA | 43.5–60 |
| Median 66 Gy | NA | 113 (59%) |
| Range (Gy) | NA | 61–72 |
Abbreviations: CR = complete response; NR = less than a partial response; NA= not applicable (in that surgeries varied); PR = partial response; XRT = radiotherapy; ER = estrogen receptor.
*
Data are numbers of patients with percentages in parentheses, unless otherwise specified.
†
Excludes 9 patients who did not receive neoadjuvant chemotherapy.